These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33007724)

  • 1. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis.
    Chen Y; Guo L; Li X; Liu R; Ren C; Du S
    Clin Neurol Neurosurg; 2020 Nov; 198():106239. PubMed ID: 33007724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
    Levin VA; Chan J; Datta M; Yee JL; Jain RK
    J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
    Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
    J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
    Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
    Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
    Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.
    Cho SJ; Kim HS; Suh CH; Park JE
    Korean J Radiol; 2020 Jul; 21(7):908-918. PubMed ID: 32524791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
    Liu Y; Feng F; Ji P; Liu B; Ge S; Yang C; Lou M; Liu J; Li B; Gao G; Qu Y; Wang L
    Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of recurrent high-grade gliomas treated with bevacizumab: A preliminary report of 3D pseudocontinuous artery spin labeling.
    Lyu Y; Liu S; You H; Hou B; Wang Y; Ma W; Feng F
    J Magn Reson Imaging; 2017 Aug; 46(2):565-573. PubMed ID: 27902863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
    Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
    Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study.
    Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E
    Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer.
    Liu CH; Kung YH; Chien-Fu Lin J; Chuang CM; Wu HH; Jiang LY; Shih YC; Wang PH; Chen YJ
    J Chin Med Assoc; 2021 Dec; 84(12):1139-1144. PubMed ID: 34610623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
    Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
    PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
    Marwah R; Xing D; Squire T; Soon YY; Gan HK; Ng SP
    J Neurooncol; 2023 Sep; 164(3):505-524. PubMed ID: 37733174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing bevacizumab dosing in glioblastoma: less is more.
    Ajlan A; Thomas P; Albakr A; Nagpal S; Recht L
    J Neurooncol; 2017 Oct; 135(1):99-105. PubMed ID: 28667595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
    Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
    J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.